Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Featured News

    Cracking the Code of Deadly Venezuelan Equine Encephalitis

    By Global Biodefense StaffNovember 29, 2016
    Genomic Research Viruses
    Share
    Facebook LinkedIn Reddit Email

    Genomic Research VirusesVenezuelan equine encephalitis virus (VEEV) has a mortality as high as 80 percent in infected animals. It causes rapid, catastrophic swelling of the brain and spinal cord, leading to severe neurological symptoms and–in many cases–sudden death. The virus can also infect humans, with similar results.

    The U.S. and Soviet Union both weaponized VEEV during the Cold War, prompting the Centers for Disease Control and the National Institutes of Health to classify VEEV as a category B pathogen.

    A research team led by the University of Maryland has exploited a weakness in VEEV’s genetic code, resulting in a far less deadly mutant version of the virus when tested in laboratory mice.

    The new discovery could enable the development of a vaccine and other drugs to combat VEEV. The findings were published last week in the Journal of Virology.

    Like many other dangerous viruses, VEEV has RNA as its genetic material instead of DNA. Because a similar weakness exists in RNA viruses that pose serious health risks to humans–such as HIV, Zika, chikungunya and others–the discovery could advance the development of treatments for these viruses as well.

    “RNA viruses tend to cause acute infections,” said Jonathan Dinman, professor and Chair of the UMD Department of Cell Biology and Molecular Genetics, who is the senior author on the research paper. “You either fight them off quickly, like the common cold, or they overwhelm you, like Ebola.”

    Dinman and his colleagues exploited a mechanism known as programmed ribosomal frameshifting (PRF), which allows RNA viruses to pack a larger amount of genetic information into a relatively short sequence of RNA. By prompting an infected cell to read the same sequence of RNA in two different phases, PRF allows a virus to create two different proteins instead of one.

    The researchers created a mutant version of VEEV with a disrupted PRF mechanism, which impaired the virus’ ability to create a second protein from a specific section of RNA. Tests in cultured cells did not reveal a large difference in the rate of virus production. But when the researchers tested the mutant virus in laboratory mice, they saw a dramatic increase in the rate at which infected mice survived the disease.

    “With some simple mutations, we compromised VEEV’s ability to be a virulent virus,” said Joe Kendra, a biological sciences graduate student at UMD and the lead author of the study. “This result shows that PRF might be a therapeutic target for other viruses. If we can confirm that the mutant virus confers immunity, opening the door to a vaccine, that will be very exciting.”

    In addition to a higher survival rate of mice infected with mutant VEEV, the researchers also noted a lower incidence of the virus accumulating in brain tissues. Dinman, Kendra and their co-authors suspect that the missing protein in the mutant virus plays a role in the virus’ ability to cross the blood-brain barrier–an essential step to cause brain swelling.

    “It’s interesting that the virus uses PRF to survive, but we can also manipulate that mechanism to work against it,” said study co-author Yousuf Khan, an undergraduate biological sciences major and Goldwater Scholar at UMD. “This is a new way to target viruses and make vaccines. It opens up a lot of new research questions.”

    According to Dinman, the finding is particularly encouraging in light of the challenge posed by climate change, as viral diseases begin to extend their range north beyond the tropics.

    “So many of these diseases are borne by mosquitoes. Chikungunya is now established in the Caribbean, and Zika has been found in two counties in Florida,” Dinman said. “These viruses are on our doorstep. But these results give us hope. Developing a vaccine takes a long time, but with a concerted effort across government and academic labs, we have a good chance.”

    Equine Encephalitis Select Agents
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleZika in Fetal Brain Tissue Responds to Popular Antibiotic Azithromycin
    Next Article Better Surveillance Needed Against Rift Valley Fever Outbreaks

    Related Stories

    Provide Feedback on Federal DURC Biosafety Oversight of Potential Pandemic Pathogens

    September 24, 2023

    New Method Improves Quantification of Ricin in Complex Matrices

    September 20, 2023

    Mass Spec for Rapid Detection of Biological Warfare Agents

    September 15, 2023

    Field Detection of Botulinum Neurotoxin with Acoustic Wave Sensors

    September 15, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy